Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults

[1]  J. Oliveira,et al.  Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  J. Oliveira,et al.  Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. , 2008, Molecular genetics and metabolism.

[3]  R. Garrick.  Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease , 2008 .

[4]  W. Wilcox,et al.  WITHDRAWN: 61 Females with X-linked Fabry disease frequently have significant organ involvement , 2007 .

[5]  D. Warnock,et al.  Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. , 2007, Journal of the American Society of Nephrology : JASN.

[6]  J. M. Aerts,et al.  Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg , 2007, PloS one.

[7]  D. Kent,et al.  Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[8]  R. Schiffmann,et al.  Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. , 2007, Journal of the American Society of Nephrology : JASN.

[9]  J. Charrow,et al.  Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. , 2007, Journal of the American Society of Nephrology : JASN.

[10]  D. Warnock.  Enzyme replacement therapy and Fabry kidney disease: quo vadis? , 2007, Journal of the American Society of Nephrology : JASN.

[11]  B. Palmer.  Proteinuria as a Therapeutic Target in Patients with Chronic Kidney Disease , 2007, American Journal of Nephrology.

[12]  D. Sillence,et al.  Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry , 2007, Journal of Inherited Metabolic Disease.

[13]  R. Schiffmann.  Enzyme Replacement in Fabry Disease: The Essence Is in the Kidney , 2007, Annals of Internal Medicine.

[14]  J. Oliveira.  Staging of Fabry disease using renal biopsies. , 2007, Clinical therapeutics.

[15]  W. Wilcox,et al.  Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life , 2007, Genetics in Medicine.

[16]  M. J. Moore,et al.  Fabry disease: a morphologic study of 11 cases , 2006, Modern Pathology.

[17]  S. Brodie,et al.  Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement , 2006, Genetics in Medicine.

[18]  S. Feriozzi,et al.  Enzyme replacement therapy and renal function in 201 patients with Fabry disease. , 2006, Clinical nephrology.

[19]  G. Houge,et al.  Prevalence of uncontrolled hypertension in patients with Fabry disease. , 2006, American journal of hypertension.

[20]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[21]  D. Warnock,et al.  Diagnosis and management of kidney involvement in Fabry disease. , 2006, Advances in chronic kidney disease.

[22]  C. Wanner,et al.  Clinical benefit of enzyme replacement therapy in Fabry disease. , 2006, Kidney international.

[23]  J. M. Aerts,et al.  Manifestations of Fabry disease in placental tissue , 2006, Journal of Inherited Metabolic Disease.

[24]  R. Schiffmann,et al.  Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  D. Hughes,et al.  Natural history of Fabry disease in females in the Fabry Outcome Survey , 2005, Journal of Medical Genetics.

[26]  S. Packman,et al.  Agalsidase-Beta Therapy for Advanced Fabry Disease A Randomized Trial , 2006 .

[27]  S. Adler,et al.  Chloroquine-induced lipidosis mimicking Fabry disease , 2005, Modern Pathology.

[28]  G. Sunder-Plassmann,et al.  Measurement of renal function in patients with Fabry disease , 2005, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[29]  D. Warnock.  Fabry disease: diagnosis and management, with emphasis on the renal manifestations , 2005, Current opinion in nephrology and hypertension.

[30]  J. Dambrosia,et al.  Pediatric Fabry Disease , 2005, Pediatrics.

[31]  G. Houge,et al.  Fabry disease: overall effects of agalsidase alfa treatment , 2004, European journal of clinical investigation.

[32]  R. Schiffmann,et al.  Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. , 2004, Kidney international.

[33]  R. Desnick.  Enzyme replacement therapy for Fabry disease: lessons from two α-galactosidase A orphan products and one FDA approval , 2004, Expert opinion on biological therapy.

[34]  R. Desnick,et al.  Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. , 2004, American journal of human genetics.

[35]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[36]  R. Mignani,et al.  Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. , 2004, Kidney international.

[37]  A. Mehta,et al.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey , 2004, European journal of clinical investigation.

[38]  K. Macdermot,et al.  Natural history of Fabry disease in affected males and obligate carrier females , 2001, Journal of Inherited Metabolic Disease.

[39]  U. Ramaswami,et al.  The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents , 2003, European Journal of Pediatrics.

[40]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[41]  S. Packman,et al.  Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy , 2003, Annals of Internal Medicine.

[42]  R. Colvin,et al.  Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. , 2002, Kidney international.

[43]  J. Alroy,et al.  Renal pathology in Fabry disease. , 2002, Journal of the American Society of Nephrology : JASN.

[44]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  R. Schiffmann,et al.  Natural History of Fabry Renal Disease: Influence of α-Galactosidase A Activity and Genetic Mutations on Clinical Course , 2002, Medicine.

[46]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  C. Eng,et al.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. , 2001, The New England journal of medicine.

[48]  D. F. Moore,et al.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial. , 2001, JAMA.

[49]  S. Brodie,et al.  A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. , 2001, American journal of human genetics.

[50]  A. Ojo,et al.  Excellent outcome of renal transplantation in patients with Fabry's disease. , 2000, Transplantation.

[51]  G. Tognoni,et al.  Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  F. Valderrábano,et al.  Report on management of renal failure in Europe, XXIV, 1993. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[53]  S. Tsuji.  [Alpha-galactosidase A deficiency--Fabry's disease]. , 1988, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[54]  D. Droz,et al.  Early renal changes in hemizygous and heterozygous patients with Fabry's disease. , 1978, Kidney international.

[55]  R. Brady,et al.  Fabry's Disease: Antenatal Detection , 1971, Science.

[56]  K. N. Benthin.  Report to Management , 1956 .